Disposable Surgical Package Blister
Diaposable surgical kit blister
1. Sterility: the device can be ultimately sterilized in one or more ways, and the material will not be degraded in the specified time;
2. Storage period: ensure the stability of the so-called barrier during the whole life cycle of the product;
3. Environmental aspects: isolation of water, air, bacteria, oxygen;
4. Physical: can provide dynamic protection, resist impact and wear, and provide structural support.
surgical kit, surgical package, surgical kit blister taicang hexiang packaging material co.,ltd , https://www.medpackhexiang.com
Drug coated balloon
Director Wu Hao speaks at the academic conference
At present, the mainstream treatment is minimally invasive endovascular treatment, which is treated by balloon dilatation and stent placement to restore vascular patency. There are still some patients with hyperplasia of the intima, and blood vessels reappear after treatment.
Drug-coated balloon (DCB), the surface of the balloon used to dilate the stenosis of the blood vessel is coated with drugs such as paclitaxel and rapamycin that inhibit intimal hyperplasia, and the drug is released while expanding the lesion. The intima of the blood vessels inhibits the proliferation of the intima, increases the patency of the blood vessels, and reduces the chance of reoperation. On May 25, the first domestic drug-coated balloon was officially listed by the State Food and Drug Administration.
In the world's leading medical journals such as New England Medicine and Circulation, a number of well-known clinical studies have been published, confirming that the patency rate of the drug-coated balloon is higher than that of a normal balloon (Percutaneous transluminal angioplasty (PTA), and the rate of restenosis, reintervention The rate is lower than the normal balloon. The drug-coated balloon has the same therapeutic effect as the metal stent and the drug-coated stent, and its significant advantage is to reduce or even avoid placing the stent in a suitable case. For patients with vascular stenosis after stent placement, drug-coated balloon therapy also has a good clinical effect. With the approval of the first drug-coated balloon in China this year, the era of peripheral drug application is coming, providing internationally advanced treatment concepts and more options for patients with lower limb ischemia, so that more patients with lower limb ischemia benefit.
The Department of Vascular Surgery of Beijing Changhua Chang Gung Hospital is one of the first centers in China to carry out drug-coated balloon treatment. Director Wu Hao has made several academic reports on the future of endovascular treatment of iliac arteriosclerotic occlusive disease in domestic academic conferences, pointing out that the drug is coated. Balloon is the future direction of the treatment of lower limb ischemic diseases. The combination of new techniques such as ballooning, plaque resection or volume reduction can improve the therapeutic effect of lower limb ischemia. Beijing Tsinghua Chang Gung Hospital has a technical level and advanced treatment concept for treating lower limb ischemic diseases, and has carried out a number of new technologies including drug-coated balloons, thrombus plaque aspiration and rotary cutting, and achieved good results.
[China Pharmaceutical Network Technology News] On June 16, Wu Wei, director of the Department of Vascular Surgery at Beijing Changqing Chang Gung Hospital, led a team of doctors to take the lead in applying the new drug-coated balloon technology in China to successfully treat patients with lower limb ischemia. The patient, Mr. Liu, was treated as “intermittent claudication for 2 years, aggravated in January†by Beijing Tsinghua Chang Gung Memorial Hospital. After diagnosis, it was “lower extremity arteriosclerotic occlusive diseaseâ€. Lower extremity arterial CT angiography showed severe stenosis of the right femoral artery. Before the operation, Director Wu Yan of the Department of Vascular Surgery, Chang Gung Hospital of Beijing Tsinghua University analyzed the patient's condition. The patient was a short-segment stenosis lesion, and the long-term effect of the drug-coated balloon was better. On June 16, 2016, Director Wu led Tsinghua Chang Gung vascular surgery team Zhao Keqiang, Zhao Junlai, and Cao Zhanjiang to perform a superficial femoral artery balloon dilatation surgery for the patient. Postoperative angiography showed that the patient's lower extremity blood flow recovered, intermittent. The symptoms of limp disappeared. "Lower extremity arteriosclerosis obliterans" is the formation of atherosclerotic plaque on the inner wall of lower extremity arteries, resulting in narrowing of the vascular lumen, symptoms of lower limb ischemia, intermittent claudication, pain, chills, numbness and the like. There are about 20 million patients with lower extremity arteriosclerosis obliterans in China. The incidence rate is 3-10% in people under 70 years old and 15-20% in people over 70 years old. The majority of the patients are male, mostly in the elderly.